The weight loss drug Wegovy lowered heart attack risk in a large trial

It Cleveland Clinic risk of dying A. Michael Lincoff — over the roughly 40 months patients participated in the study.

In the United States alone, more than 6 million obese or overweight people have cardiovascular dis Wegovy ut not diabetes.

Participants on semaglutide were sligh 20 percent ik Lincoff drop out o November 11 than those taking the placebo.

That difference seemed to the roughly 40 months ’s gastrointestinal side effects, which include Lincoff diarrhea and vomiting.

The number of serious issues that occurred, like cancer or infection, was slightly lower in the group. n’t 2 an class="summaryFeed_highLightText__NxlGi">Powell-Wile obese an> first >Hispanic African-American the United States Tiffany Powell-Wiley ightText__NxlGi">Lincoff the National Heart _h Lung ightT Blood Institute perc Bethesda n> Md. span the United States ed_highL more than 6 million obese nt Powell-Wiley t Powell-Wiley an> SELECT Lincoff Novo Nordisk’s Powell-Wiley n Harvard Medical School and Brigham and Women’s Hospital Caroline Apovian one first 29/23 SN Semaglutide s="summaryFeed_highLightText__NxlGi">August November 8 Te the U.S. Food and Drug Administration class="summaryFeed_highLightText__NxlGi">Khera Zepbound NxlGi">obese FAQ las Semaglutide eed_highLightText__NxlGi">ov Ozempic t< first > 2017 >November 10 2020 lGi">L FDA off Dallas 2021 eed_highLightText__NxlGi">UT Southwestern Medi Wegovy nter Lincoff summaryFeed_highLightText__Nx SELECT mit Kheramore than 17,000 ss="summa half ed_highLightText__ weekly >two roughly three years t__NxlGi">fi half /span> 8 percent lGi">Time Wegovy 17,0006.5 percent ass="summaryFeed_highLightT Lincoff lGi">the New England Journal of Medi November 11